Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Carlsmed Q3 2026 Results: Net Loss of $12.2M, Loss Widens

Carlsmed, Inc. reported revenue of $56.6 million for the nine months ended September 30, 2026, a significant increase from $35.3 million in the prior year period. Despite the revenue growth, the company recorded a net loss of $31.5 million for the first nine months of 2026 as operating expenses, particularly in sales, marketing, and general administration, increased substantially.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue21.613.1
Gross profit16.79.9
Net income-12.2-8.5
EPS (diluted, $ a share)$-0.45$-0.40

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+64.9%
Gross margin77.3%
Operating margin-58.9%
Source

10-Q filed with the SEC, NASDAQ: CARL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Carlsmed, Inc.: key numbers

Share price
$17.35Close, Nov 16
Market cap
$475M
Shares outstanding
27.4MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Carlsmed, Inc.

All →
4:06 PM ET 8-K
Financial Results

Carlsmed Financial Results

Carlsmed reported Q3 2026 revenue of $21.6 million, a 65% increase year-over-year, driven by a 60% expansion of its surgeon user base. The company raised its full-year 2026 revenue guidance to $78-$80 million and highlighted new CMS inpatient reimbursement for its aprevo lumbar spine fusion procedure.

Term
Q3 2026

“The third quarter represented strong execution against our long-term strategy as we delivered 65% revenue growth and advanced our leadership position in AI-enabled personalized surgery as we grew our surgeon user base by more than 60% over the prior year.”

Mike Cordonnier, Chairman and CEO

“We broadened our personalized surgery platform, strengthened our leadership team, and secured new inpatient CMS reimbursement for our aprevo® lumbar spine fusion procedure. Taken together with our differentiated, capital-light model, these accomplishments reinforce our foundation for sustainable, profitable long-term growth as we head into 2027.”

Mike Cordonnier, Chairman and CEO
4:40 PM ET Form 4
Insider Selling

Carlsmed COO Jeffrey Bertolini Sells $11.3K of Stock

Jeffrey Bertolini, COO, sold 747 shares of Carlsmed, Inc. at $15.15 a share, worth $11.3K in total on Nov 3, 2026. Shares held after the trade: 22,489 (-3.2%).

Value
$11.3K
Shares
747
Price
$15.15
Role
COO
Holding change
-3.2%
Trade date
Nov 3, 2026
4:59 PM ET Form 4
Insider Selling

Carlsmed COO Jeffrey Bertolini Sells $10.7K of Stock

Jeffrey Bertolini, COO, sold 747 shares of Carlsmed, Inc. at $14.39 a share, worth $10.7K in total on Oct 5, 2026. Shares held after the trade: 22,489 (-3.2%).

Value
$10.7K
Shares
747
Price
$14.39
Role
COO
Holding change
-3.2%
Trade date
Oct 5, 2026
9:16 AM ET 8-K
Leadership Change

Carlsmed Leadership Change

Carlsmed appointed Richard Heppenstall as Chief Financial Officer, effective September 28, 2026, succeeding Leo Greenstein who departed the role. Mr. Greenstein will receive a $500,000 cash severance payment and accelerated equity vesting, while also serving as an advisor through the end of 2026. The company reaffirmed its full-year 2026 revenue guidance of $74 million to $78 million in conjunction with the transition.

Counterparty
Richard Heppenstall

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.